An Open-label, Pharmacokinetic Study of Lenalidomide (Revlimid) and High-dose Dexamethasone Induction Therapy in Previously Untreated Multiple Myeloma Patients With Various Degrees of Renal Dysfunction - Validation of Official Dosing Guidelines for Renal Failure
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Pharmacokinetics
- 19 Sep 2017 Planned End Date changed from 1 Aug 2017 to 31 Dec 2018.
- 19 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Dec 2017.
- 01 May 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.